Multiply Labs' leverage of NVIDIA’s tech stack marks a turning point for a biomanufacturing industry that has historically relied on manual, "artisanal" processes. By integrating NVIDIA’s digital ...

Cell therapies are among the most promising, yet complex medicines being developed today. Multiply Labs' mission is to make these therapies more widely available by increasing manufacturing efficiency ...

Multiply Labs collaborated with these life science industry leaders to demonstrate automated cell therapy manufacturing tasks, with an emphasis on cell expansion. The results of the proof-of-concept ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Retro Biosciences (Retro), a ...

Portal Biotechnologies and Multiply Labs announced a collaboration with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more ...

Multiply Labs, a robotics firm, and Retro Biosciences, which is developing therapies to address age-related diseases, signed an agreement valued at up to $85 million to automate Retro’s approach to ...

Robotic biomanufacturing company Multiply Labs said it has made a significant advance toward its goal of scaling production of cell and gene therapies by using Nvidia’s open Isaac and GR00T robotics ...

Breakthrough partnership with Universal Robots transforms "artisanal" manufacturing, making personalized, life-saving cancer treatments affordable and widely available. Leveraging collaborative robots ...

Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA’s open ...

Collaboration with AstraZeneca will focus on scaling cell therapy manufacturing using GMP-ready end-to-end robotic biomanufacturing technology SAN FRANCISCO--(BUSINESS WIRE)--#AstraZeneca--Multiply ...

Multiply Labs, a leader in robotic biomanufacturing, today announced a landmark milestone in its mission to scale production of cell and gene therapies; The company is now leveraging NVIDIA's open ...